Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.47 |
| ▸ | TACR3 | P29371 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6011641 | 1.00 | KDM4E (0.50) | KDM4ESMN1; SMN2ALDH1A1UCHL1TACR3 | |
| SCHEMBL375146 | 1.00 | KDM4E (0.50) | KDM4ESMN1; SMN2ALDH1A1UCHL1TACR3 | |
| SCHEMBL2617528 | 1.00 | KDM4E (0.50) | KDM4ESMN1; SMN2ALDH1A1UCHL1TACR3 | |
| SCHEMBL9971085 | 0.94 | KDM4E (0.48) | KDM4ESMN1; SMN2ALDH1A1UCHL1TACR3 | |
| SCHEMBL13123350 | 0.94 | KDM4E (0.48) | KDM4ESMN1; SMN2ALDH1A1UCHL1TACR3 | |
| SCHEMBL8275065 | 0.94 | KDM4E (0.48) | KDM4ESMN1; SMN2ALDH1A1UCHL1TACR3 | |
| SCHEMBL12744677 | 0.92 | KDM4E (0.47) | KDM4ESMN1; SMN2ALDH1A1UCHL1TACR3 | |
| SCHEMBL14035546 | 0.92 | KDM4E (0.47) | KDM4ESMN1; SMN2ALDH1A1UCHL1TACR3 | |
| SCHEMBL16938888 | 0.92 | KDM4E (0.47) | KDM4ESMN1; SMN2ALDH1A1UCHL1TACR3 | |
| SCHEMBL13340509 | 0.91 | KDM4E (0.46) | KDM4ESMN1; SMN2ALDH1A1UCHL1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216725-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216725-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7323447-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| WO-2006086381-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216725-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ZC3HAV1, VIP, O60361 | KDM4E 493/4885SMN1; SMN2 4686/4885ALDH1A1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.